Takeda is an R&D driven, global biopharmaceutical leader. For 240 years, we’ve focused on bringing better health and a brighter future to people around the world by translating science into life-changing medicines that make a critical difference for patients.
Our R&D engine has produced exciting new molecular entities (NMEs) across our core Therapeutic Areas: Oncology, Rare Genetics and Hematology, Neuroscience and Gastroenterology. In these areas, we’re focused on targeted patient populations where we’re able to deliver the greatest therapeutic benefit for patients.
Our pipeline is projected to deliver value in two distinct waves. In the near-term through FY2024, there are 11 NMEs with the potential for 15 launches, representing best-in-class or first-in-class therapies.
Looking to FY2025 and beyond, our R&D engine with internal research capabilities and external partnerships is expected to deliver a steady stream of next-generation therapies that will sustain our growth. These programs leverage new platform capabilities in cell therapy, gene therapy and data sciences.